直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Securing $240 million and a jury verdict of willful infringement for Promptu in patent case against Comcast

Promptu Systems Corporation

US Synthetic secures ITC exclusion order barring polycrystalline diamond compacts (PDCs)

US Synthetic Corporation

Achieving precedent in preserving valuable patents for Lumify®

Eye Therapies, LLC

Finnegan client Maglula delivers crushing blow to Amazon’s arbitration practices over counterfeit products

Maglula, Ltd.

Finnegan secures $180M for CSRC in complex arbitrations

CSRC et al.

Protecting a blockbuster diabetes treatment for AstraZeneca

AstraZeneca AB

Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini

Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.

Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement

Eisai Co., Ltd.

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Intellia Therapeutics, Inc.

Recent Experience

Experience

 Arvinas Operations, Inc. et al. v. Qian et al.

 Arvinas Operations, Inc. et al. v. Qian et al.

3:22-cv-00717, D. Conn., Judges Chatigny, Richardson

Experience

Representative Engagement: Protecting a blockbuster diabetes treatment for AstraZeneca - AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc., 1:18-cv-00664, D. Del.

Protecting a blockbuster diabetes treatment for AstraZeneca Protecting a blockbuster diabetes treatment for AstraZeneca

1:18-cv-00664, D. Del., Judge Andrews

Experience

Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al. Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.

1:21-cv-00870, D. Del., Judge Hall

Experience

CMC Materials, LLC v. Dupont de Nemours, Inc. et al. CMC Materials, LLC v. Dupont de Nemours, Inc. et al.

1:20-cv-00738, D. Del., Judge Hall

Dupont de Nemours, Inc. et al.

Experience

Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc.  Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc. 

2:15-cv-08180, 2:17-cv-06714, D.N.J., Judges Chesler, Waldor

Experience

Valeant Pharmaceuticals NA, LLC v. Zydus Pharmaceuticals, Inc. Valeant Pharmaceuticals NA, LLC v. Zydus Pharmaceuticals, Inc.

3:17-cv-00449, D.N.J., Judges Sheridan, Goodman

Experience

Flexsys America L.P. v. Process Engineering Associates LLC Flexsys America L.P. v. Process Engineering Associates LLC

3:16-cv-00311, E.D. Tenn., Judges Mattice, Guyton

Experience

Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc. Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc.

2:16-cv-00217; 2:17-cv-00544, -01568, D.N.J., Judges Chesler, Waldor

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP